PacBio Files 8-K/A Amendment on Officer/Director Changes

Ticker: PACB · Form: 8-K/A · Filed: 2025-02-07T00:00:00.000Z

Sentiment: neutral

Topics: leadership-change, officer-appointment, director-election, compensation

Related Tickers: PACB

TL;DR

PacBio amended its 8-K, reporting leadership shakeups and compensation changes effective Jan 24.

AI Summary

Pacific Biosciences of California, Inc. filed an amendment (8-K/A) on February 7, 2025, reporting changes effective January 24, 2025. The filing concerns the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers.

Why It Matters

This amendment to a previous filing indicates significant changes in the company's leadership structure and executive compensation, which could impact strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in key leadership and executive compensation can signal internal shifts or strategic realignments that may carry inherent business risks.

Key Players & Entities

FAQ

What specific officer or director positions were affected by this amendment?

The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' but does not specify the names or exact roles in the provided excerpt.

What is the effective date of the reported changes?

The earliest event reported is dated January 24, 2025.

When was this amendment filed with the SEC?

This amendment was filed as of February 7, 2025.

What type of SEC filing is this?

This is a Form 8-K/A, an amendment to a current report.

What is the primary business of Pacific Biosciences of California, Inc.?

The company is involved in 'LABORATORY ANALYTICAL INSTRUMENTS' with SIC code 3826.

From the Filing

0001299130-25-000027.txt : 20250207 0001299130-25-000027.hdr.sgml : 20250207 20250207170835 ACCESSION NUMBER: 0001299130-25-000027 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250124 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250207 DATE AS OF CHANGE: 20250207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 25602795 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K/A 1 pacb-20250124.htm 8-K/A pacb-20250124 0001299130 true DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. 0001299130 2025-01-24 2025-01-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2025 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. Pacific Biosciences of California, Inc. (the “Company”) is filing this amendment to its Current Report on Form 8-K filed on January 30, 2025, which reported that the Company’s Board of Directors (the “Board”) had appointed Christ

View on Read The Filing